CA2096006A1 - Intraretinal delivery and withdrawal instruments - Google Patents
Intraretinal delivery and withdrawal instrumentsInfo
- Publication number
- CA2096006A1 CA2096006A1 CA002096006A CA2096006A CA2096006A1 CA 2096006 A1 CA2096006 A1 CA 2096006A1 CA 002096006 A CA002096006 A CA 002096006A CA 2096006 A CA2096006 A CA 2096006A CA 2096006 A1 CA2096006 A1 CA 2096006A1
- Authority
- CA
- Canada
- Prior art keywords
- tip
- eye
- instrument
- intraocular
- distal end
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00736—Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M2025/0042—Microcatheters, cannula or the like having outside diameters around 1 mm or less
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0612—Eyes
Abstract
An intraretinal delivery and withdrawal instrument and methods for entering the eye directly without a surgical incision as a prerequisite. The instrument has (a) a handle (10) and a curved, distal frame (12) extending therefrom, for insertion into an orbit along the periphery of the eye (18) in a direction so as to reach the posterior of the eye; (b) a tip (14) connected to the frame for penetration into the subretinal region of the eye; and (c) an adjustable collar (24) connected to the tip whereby the collar is capable of being positioned so that the collar regulates the depth of tip penetration into the subretinal region.
Description
W092/0~06 PCT/~S91/0~68 2~96~G
I~T}~R13TINA~ DE~ VERY AND WIT}IDR2.WAL IN8TRllM~NTS
BACRGRO~ND AND ~MM~RY OF THE INV~NTION
The invention ls in the field of medlcal devices for intraocular sample delivery and withdrawal. More particularly, it pertains to instruments shaped and ~imensioned for insertion into the orbit along a~ insertion path which extends along the periphery of the eye in a posterior direction to place the instrument tip adjacent to the posterior portions of the eye such as the sclera, choroid, the retina, or vitreous chamber.
Throughout this application various publications and patents are referenced and citations are provided in parentheses for them. The disclosures of these publications in their entireties are hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains.
The remarkable efficiency of the eye as an organ for vision results from its highly specialized organization and the complicated coordination of its component parts which are vital to the process of normal vision. Damage to any essential structure can result in impairment of vision.
Accordingly, it is particularly important that instruments designed for use in or around the eye (ocular globe) to aid in treatment or diagnosis of visual impairment must be safe and reliablej while at the same time permitting access to regions of the eye that are not easily accessible.
A common feature of kncwn prior art intraocular transplantation instruments is that they carry out sample delivery by penetrating an anterior part of the eye, i.e.
via a transcorneal or transcleral route, which crPates the risks of corneal ulceration, cataract formation, and other anterior penetration prob~ems. One exemplary prior art lnstrument is a microspatula which administers cells to the W092/0~06 PCr/~S91/08468 20~6G~6 eye through a trans-scleral or trans-corneal surgical incision (12). Another exemplary prior art instrument is a glass micropipet which replaces cells in the retina by entering the eye anteriorly through an incislon via the scleral route (10). Yet another exemplary instrument is a glass micro canula which effects transplantation of cells into the retina by entering the eye anteriorly through a surgical incisio~ via a trans-scleral or trans-corneal route.
, Known prior art instruments do not directly effect entry into the eye. Instead, an entry portal, i.e. a surgical incision, is believed to be necessary. Surgery involves inherent risks and possi~le complications such as vitreous loss~ cataract formation, and intraocular infection. Of course, any instrument which requires surgical procedures before it could be used is less desirable than instruments which do not. Further, because such prior art instruments effect entry through surgical incisions, any attempts to implant at multiple sites within the eye can be exceedingly difficult and dangerous.
In contrast, the subject invention provides instruments which can entér the eye directly, without reguiring a surgical incision as a prerequisite. Importantly, the subject invention makes it possible to transplant at multiple sites within the eye without the undesirable risks and consequences of multiple surgical procedures.
Further, in contrast to the prior art instruments, the subject invention provides a particularly effective way to control the depth of intraocular penetration. One embodiment of the invention uses a uniquely shaped and positioned adjustable collar to regulate the depth to which the instrument tip may enter the intraocular area. In contrast, it is believed khat known prior art instruments cannot be pre-set to penetrate only to a pre-determined ~'','.
W092/0~0~ PCr/US9~/08468 ~S~Q~ `
desired depth; instead, the penetration depth into the intraocular area is determined at the time of penetration.
These instruments do not have the advantage of effecting intraocular penetration at a predetermined depth. This S feature is believed to be particularly important because the ability to limit the actual penetration depth of -an intraocular instrument could alleviate or eliminate important disorders or symptoms that can be associated with intrusion into the intraocular area. Anothsr important benefit i5 the invention's ability to have a pre-set or predetermined depth of penetration into the eye, is that sample delivery or withdrawal can be pinpo:inted at the desired part of the eye, e.g. only the scleral area, the choroid area, the retinal area, the sub-retinal area, or the vitreous area, etc.
',.
The known prior art instruments typically provide sample delivery but not sample withdrawal with the same instrument~
Further, it is believed that the known prior art instrument cannot be e~fectively pre-set to dispense only a desired volume but rather dispense the sample according to the pressure exerted by, or movement of, the operator at the time of sample delivery, i.e. sample size is not predetermined and dispensed before the instrument is in the eye. Accordingly, prior to the procedure of eye p~netration, there is an effective way to be sure that only a predetermined amount of sample will in fact be administered to or withdrawn from the intraocular area.
.
The invention is believed to provide a new and relîably reproducible means for retinal transplantation without a surgical procedure on the eye as a prerequisite. In contrast, the known literature proposes techniques for intraretinal transplantation which r~quire surgically opening the eye. Lopez, et al. (10) discuss a technique which required making a pars plana incision and inserting a micropipette through the globe into the subretinaI space.
,:. :' ' . ' W092/0~06 PCT/US91/084~8 2 0 ~ 6 4 The method described by Lopez involves forming a retinal detachment in order to properly place the transplant. They note that "there are a number of potential pitfalls associated with this technique" and remark that the host epithelium must first be detached. This is a procedure whlch in the case of the human eye can be associated with subretinal neovascularization. In addit:ion they note that "it may be difficult to be certain that no cells enter the vitreous cavity."
The technique proposed by Sheedlo et al. (ll) rec~ires excision of the superior rectus muscle, followed by an incision into the globe with a blade which penetrate.s the sclera and choroid to expose the subretinal space, prlor to performing the transplantation of cells into this locus.
Following the injection of material, the incision must be closed surgically with suture material.
Silverman and Hughes (12) report a technique which also involves a preliminary ocular incision prior to implantation of tissue. ~hey propose a trans-corneal approach to t~e , .
subretinal space which involves making a transverse incision through the cornea and then traversing the entire gIo~e in order to reach the posterior pole.
BRI~F D~8C~IP~ION OF TH~ p~AWING8 Figure l illustrates a sample delivery and withdrawal instrument in accordance with an exemplary embodiment of the invention.
Figure 2 illustrates access to a posterior portion of the eye using the instrument of Fig. l.
35 ; Figures 3a and 3b illustrate in more detail the tip end of ;;
the instrument of Fig. l and the way the tip is mounted.
',:
: . ., :....
' ' ' ' W092/0~06 PCT/U~91/0~68 2 ~ a ~
Figures 4a and 4b illustrate an alternate way of mounting the instrument tip.
Figure 5 illustrates a prior art technique for rotating the eye so that a posterior portion can be accessed but also illustrates access into a posterior portion of the eye using an instrument tip which can deliver or withdraw a predetermined amount of material in accordance wi~h a feature of the invention.
DBTAI~ED DE8CPcIPTION OF T~IE INVENTION
Referring to Figures 1-4a, an exemplary instrumerlt for withdrawal and delivery of a sample from and to a postPrior part of the eye, has an elongated handle lO having a distal end lOa and a proximal end lOb. Handle 10 is shaped and dimensioned to be grasped by the hand of the user carrying out the procedure of withdrawal or delivery of a sample ~rom or to a posterior part of the eye. The instrument further comprises an elongat~d and curved frame 12 extending ~rom the distal end lOa of handle lO. Frame 12 has a distal end 12a to which a tip 14 is attached. Frame 12, or at least the distal part thereof, and tip 14 are shaped and dimensioned for insertion into an eye orbit along an insertion path (Fig. 2) which extends along the periphery o eye 1~ so as to place tip 14 adjacent to the retina~ or subretinal region 20 and in the direction for penetration into the subretinal region of the eye when said tip ~ is moved generally in the medial direction by manipulating handle 10. A scleral depressor 12c can extend from the distal tip of frame 12, e.g., at an angle of about 4 degrees to each of tip 1~ and the adjacent part of frame 12, away from tip 14, to facilitate insertion of the rame along an insertion path around the periphery of the eye.
Handle 10 and the curved distal Erame 12 can be made of a metal such as titanium, stainless steel, tantalum, or ,,. . .. , : - ., . - .......... , - :. . -, - ~ .
~ : , . ' .... ',: ,. . . : :~ ,. - . : . - : .
, ,: ., .... , , . , - ......... . . . .
. . . - . ... - . ~ . . -W092/0~06 PCT/US9t/~84~
209~ 6 vitallium, or can be made of other suitable materials.
Alternatively, handle 10 and the curved distal frame 12 can be made of a plastic material such as a polyethylene type plastic. Tip 1~ can comprise a needle tip 22 which is made up of a metal such as titanium, stainless steel, tantalum, or vitallium~ or some other suitable material, and an adjustable collar 2~ (Figs. 3a-4b) which regulates the depth to which tip 1~ penetrates the eye, a.g., subretinal region 20 of the eye. Needle tip 22 can be the tip of a needle such as a 30 gauge or a 27 gauge needle, and extends at an angle such as a right angle to the distal end 12a of frame 12. In general, a needle tip in the range from about 32 gauge to 15 gauge would be suitable, depending on the particular patient and procedure, and depending on the physician's preference and needs.
In the example of Figs. 3a and 3b, distal end 12a tapers into a free end terminating into a central opening 12b provided with an internal screw thread mating with an external screw thread 2~a which is at one end of adjustable collar 24. Further, the degree to which needle tip 22 penetrates the eye can be varied by adjusting the extent to which thread 24~ is screwed into thread 12b. In one embodiment o~ the invention, adjustable collar 2~ is a plastic sleeve. In another, it is a metallic adjustable sleeve of the same or similar shape. While it is believed that a sufficient range of penetration depth can be provided only by the degree to which threads 2~ and 12b are screwed into each other, sleeves of different lengths may be used to extend the range. Interchangeable sleeves of different lengths or shapes can be used for other purposes as well, e.g., to accormodate special needs or preferences of the : physician and/or of the patient. Instead o' using mating threads, diff~rent sleeves that snap on or are ~rictionally or otherwise engiaged can be used. As seen in Figs. 4a and 4b, an alternative to the embodiment o~ Figs~ 3a and 3b is to have an internal thxead 2~al at one end of sleeve 24' and ' W092/0~06 PC~/US9l/08~68 7 2~6~6 ~ -an external thread 12b' at the distal end 12a' of the instrument frame.
In order to deliver or withdraw material from the eye, needle tip 22 is hollow and communicates with a passage through frame 1~ which in turn communicates with a passage through handle 10. The passage through handle 10 in turn communicates with a feed line 26 and an aspiration line ~.
Feed line 26 is in selective fluid flow communication with said hollow passage through handle 10 to deliver fluid to the eye through needle tip 22. To effect the del.ivery of a predetermined quantity of ~luid into the eye, a control circuit 30 generates a delivery command signal, e.g., in response to the manual operation of a switch (not shown) to drive a metering pump 32 which pumps into feed line 26 the desired amount of fluid. A fluid supply 34 supplies the fluid to metering pump 32. To aspirate fluid from the eye, aspiration line 28 is in selective ~luid flow commun.ication with a metering vacuum pump 36 which, in response to a similarly generated aspiration command signal from control circuit 38, pumps out the desired quantity of fluid from the eye into a vessel ~0. Of course, if desired, the instrument can be only for delivery of fluid to the eye, or only for aspiration of fluid from the eye, in which case it would have only feed line 26, and the associated components used for fluid delivery, or only aspiration line 28, and its associated components used for aspiration. Feed line 26 and aspiration line 28 can be made up o~ plastic or metal, but plastic feed and aspiration lines are currently preferred.
Referring to Fig. 5, a tip similar to that illustrated in Figs. 3a and 3b, or in Figs. 4a and 4b, which can conveniently regulate the depth of penetration into the eye, can be used in an otherwise prior art technique in accessing a posterior portion of the eye in the illustratPd manner.
W092/0~06 PCT/US91/0~68 2~6~ 8 Various modifications of the disclosed apparatus are possible. For example, while electrically operated and electronically controlled meterlng pumps 32 and 36 can be used as discussed above, in an alternate structure, it is possible to use manually operated, syringe-type delivery and aspiration tools instead.
In an exemplary procedure in accordance with the invention, donor cells were implanted as follows. Second trimester human embryonic retinal cells obtained from electively aborted embryos age 13 to 17 weeks were used as donor tissue. Procurement of donor cells was in accordance with scientific and ethical guidelines which included institutlonal review and approval of the experimental protocol. ~n all cases, maternal consent was given only after the decision to have an elective abortion was made.
The cells were prepared as follows. The eyes were obtained less than one hour after fetal death and collected in either calcium - magnesium medium or in human plasma at 4C.
operating with the aid of a surgical microscope, the eyes were dissected open. The retinas were cleanly cut away, free of contamination from either vitreous or retinal pigment epithelium. Isolated retinas were trimmed into small fragments using a Vannas scissor (Storz, St. Louis, MO), and then placed into ice cold medium. Mechanical dissociation was used to obtain suspension of retinal cells and cell clusters. The dissociation was achieved by aspirating the retinal fragments through butterfly tubing (Abbott Hospitals, North Chicago, Illinois) and then releasing them through the same needle. By varying the needle gauge and ~he number of aspiration ejected cycles it was possible to maintain fine control over the final degree of dissociation. For example, a nearly pure single cell susp nsion lS achieved by 2 cycles through a 30 gauge needle, while 1 cycle through a 27 gauge needle yields a suspension formed by clumps comprising a few hundred cells, as well as a negligible numDer of single cells. Hosts and ' ,: -, '; ' -W092/0~06 PCT/US9l/0~68 9 2 Q ~ 6 anaesthesia were used as follows. Young male adult rats of the Wistar strain served as hosts. In experiments us.ing rats, two to three groups of six rats each were used per experiment. The animals were anaesthetized with a mixture of chloral hydrate and sodium pentobarbi.tal (Chloropent, Henry Schem Inc. Port Washington, NY) at a dose of 3 ml/K~.
Topical 1% Alcaine drops (Propaine Hydrochloride, Alcon, Fort Forth, Texas) were also used as a topical anaesthetic.
The eyes were dilated pre-operatively with one drop each of 1% neo synephrine and 1% mydriacyl (Alcon, Fort Worth, Texas). The following delivery system and transplantation procedure were used. For most experiments, a 27 gauge needle tip, tigh~Iy sheathed in plastic, with 1.2-1.4 mm of the ne~dle tip left exposed, was connected to a microliter syringe (Series 1700, Hamilton, Reno, Nevada), prior to the procedure (Figure 1). The plastic collar placed on the needle serves as an adjustaple regulator. By setting it at the appropriate depth, depending on the animal model being used, the collar serves to limit the depth of penetration and provides protection against over penetration. The plastic collar can be regulated so that only enough of the needle tip is exposed to reach the subretinal space without actually penetrating th~ retina. A major advantage of a tip connected to a pIastic collar during injection into the retinal area is the prevention of large retinal holes or tears. Specifically in this example, minimal over-penetration of the tip causes part of the open portion of the bevel to be in the vitreous area, thereby leading to an intravitreal injection. The microliter syringe was preloaded with A suspension of neuroretinal cells. After the animal was appropriately anesthetized, collibri forceps (Storz, St. Louis, MO) were used to firmly grasp the sclera at the limbus and rotate the globe anteriorly. Then, using a stereo microscope for direct visualization, the needle was manually inserted through the sclera and ~ently rotated until the tip could be directly viewed through the retina, then the tip was advanced further so as to slightly elevate - : , ' ~ :
' ~ ' : ~ `:
W092/0~06 PCT/US91/08468 0 0 ~ 10 the retina. The plastic protective sheath prevents over-penetration of the needle and perforation of the neuroretina. With the bevel of the needle facing the globe, i.e. the ocular globe, the injection of cells was made.
Following the injection, the needle was quickly withdrawn and the procedure repeated at a point 180 degrees opposi~e to the first injection site in the same eye. Typically, two micro-injections were made into the equatorial region of each eye. One was made superiorly at the 12 o'clock position and the other at the 6 o'clock position inferiorly.
However, as many as four penetrations have been performed in a single rat eye and up to six into the lower hemisphere of the monkey eye. The needle was quickly withdrawn following each injection. After the experiment was completed a topical lubricant was placed on the cornea to prevent drying. Control injections were used as follows. In order to obtain instant, permanent and multilevel visuailization of the spread of the injected fluid, colloidal carbon t3,4) was used to perform control injections in the identical manner ~ -as those involving injections of cell suspensions. One group of six animals served as the control group receiving colloidal carbon injections. Colloidal carbon (Biological India Inc., Pelikan, West Germany) was prepared in a 1:4 dilution with saline. In vivo exams were used as follows.
All surgery was performed using an Olympus SZH stereo-microscope fitted with a 35mm photographic camera as well as a videotaping apparatus. The same set up was used to photograph the transplants a~ various stages of growth. For the latter purpose, either a lensing system or a slide was used in order to bring the retina into fine focus. Indirect and direct ophthalmoscopy was routinely performed on all the transplant recipients. Using a Keeler (Keeler, Broomall, Pa) indirect ophthalmoscope and a Volk Pan Retinal lens (Keeler, Broomall, Pa) the animals were examined at regular intervals. This allowed us to constantly monitor the growth and condition of the transplant. Photographs werP taken ,: .
.. ..
W092/0~06 PCT/US9~/08468 through the microscope using a NiXon camera or a Ko~a camera ln conjunction with the indirect ophthalmoscope.
The survival times and histological procedures were as follows. Survival times for the animals receiving cell injections ranged from 3 to 90 post-transplantation days (PTD). Control animals who received injections of coIloidal carbon were sacrificed three days followi~g intraocular injections. The eyes were enucleated, and the animals sacrificed under deep anesthesia using an intramuscular injection of Ketamine 100mg/ml at a dose of 90mg/kg (Quad Pharmaceuticals, Indianapolis, Indiana) and intramuscular Rompun 20mg/ml at a dose of 8mg/kg (Xylazine, Mobay Corp., Shawnee, Kansas). The eyes were enucleated and fixed in 6%
glutaraldehyde in cacodylate bu~fer for 24 to 48 hrs. They were then rinsed in buffer and split along the sagittal axis, extending from the cornea to the optic nerve. The hemisected eyes were examined and photographed under a stereomicroscope, and were then en~edded in plastic ~Eponate 12, Ted Pella, Redding, CA). One micrometer ~m) thick sections were cut and stained with Stevenel Blue (5,6) for light microscopic study. Ultra thin sections were cut with a diamond knife ~or elertron microscopic studies. They wera stained with lead acetate (7) and studied under a Zeiss 10 electron microscope operating at 8~ kilovolts ~Xv). Some of the retinas injected with colloidal carbon were dissected free and prepared as flat-mounts in order to better avaluate the extent of dif~usion of the injected fluid throughout the host retina.
The intraoperative results from the set of control experimen~s using colloidal carbon, demonstrated that the carbon is injected precisely into the sub-retinal space.
The entire procedure could be viewed directly under the operating microscope. It was possible to see how the needle penetrated the sclera and pushed the retina upward. At that point, the bevel was turned in order to put it in apposition :
W092/0~06 PCT/~'S91/08468 '~9~0~)~ 12 to the retina, at an orientation which assured proper localization of the injected material. At this point, the injection was carried out. As the two microliters of fluid were injected, the colloidal carbon was readily seen spreading over the retinal surface. The material quickly fanned out and covered anywhere from 60 to l80 ~er injection. The colloidal carbon dramatically illustrate$
the wide diffusion of the injected fluid over the surface of the host retina. It also serves as a control for the results obtained by transplanting living cells. Access to any portion of the retina, even as far poster:iorly as the region around the optic nerve head, was possible.
Clinical observations have confirmed the atraumatic nature of this techniqueO The wound is s~lf-sealing, thus requiring no surgical closure. There was no vitreal loss at the time of injection and post operative examinations showed no corneal opacities, no lenticular changes, a nor~al optic nerve head, and an intra-ocular pressure which remained stable throughout. Indirect ophthalmoscopy was negative for signs of hemorrhage, neo-vasculari2ation, uveitis or ocular -`
infection in the eyes of approximately l00 rats and 2 monkeys transplanted using this procedure.
Histological observations correlated well wlth those made by biomicroscQpy. Sections of eyes injected with a tracer and those injected with suspensions of living human fetal retinal cells showed considerable dispersion of the injected material, which spread onto the outer retinal surface from the subretinal injection point. Colloidal carbon injections dramatically illustrate the vast surface of the host retina which is covered by even a single injection. When a flat mount is made of the same preparation, it dramatically indicates the wide diffusion of the carbon granules throughout the retina. On histological specimens involving colloidal carbon injecti4ns, there is clearly intraretinal colloidal carbon materials scattered throughout.
~':
, W092/0~06 PCT/US91/08468 13 ~t~ 8 In experiments where living human fetal retinal cells were grafted, the same pattern of distribution was observed as 7 those seen in control injections, where colloidal c~rbon was introduced into the subretlnal space. Typically, the penetration point was marked by comparatively large clusters of cells, which could reach dimensions of 250 micrometers thick and 600 micrometers wide.
The initial retinal transplantation experime1lts (8) were performed using glass micropipettes attached to a microliter syringe. A preliminary incision was made through the sclera, and the transplant was then perfo~med. This technique, although very effective in the rodent model, proved to be difficult and time consuming with severe limitations on accuracy. Suturing of the minute incision in particular, was associated with a sharp increase in complications, such as retinal detachments subretinal hemorrhages, and formation of intravitreal membranes. A
modified approach was developed which avoided suturing (9) and its complications, e.g. decreased the formation of pre-retinal membranes, and sharply reduced the incidence of hemorrhaging. However, the method did not eliminate the associated problems in their entirety. Therefore, a need for devising a more expeditious and efficient means of transplantation became necessary, i.e. a method that would make multi site grafting into retinas not only possible, but virtually free from surgical complications. It i5 believed that a quick and atraumatic method could limit the complications, as well as the cellular response. A goal was to formulate a means which would be uncomplicated and quick, but at the same time guarantee that the cells would be delivered intraretinally, at multiple points, in a safe and reliable manner.
The closed eye method of transplantation is believed to be hi~hly ~esirable because it avoids the need for surgically W092/0~06 PCT/US91/08468 opening the eye and thus makes it feasible and practical to perform multiple simultaneous grafts into an intact globe.
The procedures, in accordance with the invention, have photographically demonstrated a retinal transplantation.
The methods have undergonP sufficient laboratory testlng ~o state that the cells are being delivered at the desired subretinal or intraretinal locations under direct visual control by the operator.
The procedure, in accordance with the invention, is believed o be quick and efficient and to provide the added advantage of multi-site delivery of cells over a broad surface area, and thereby to vastly improve the odds for success of the transplantation. Perhaps even more significantly, it is a benign proce~ure. Because it is quick, there is only a need for brief anaesthesia, to thereby further limit the complication rate. The rapid transplantation of cells also diminishes the risk of infection or post-operative complications. The simplicity of the procedure, an intraocular injection, means that the risk of intraoperative complication should be minimal. The rat model presents an uncomplicated approach. In all the cases performed by or for the rodent and primates (13) there have been no intra-operative or post-operative-complications.
When performing these procedures, it is desirable to use different parameters in order to test various experimental paradigms. By allowing controlled penetration of the sub-retinal and retinal spaces this technique does exactly that.
The colloidal carbon manifests precise placement o~ material on a macroscopic and histological level. When using living donor cells, the results shown by histo}ogical examination are once again the same successful intraretinal placement of cells. The results, in accordance with the invention, sugyest that a reproducible procedure of intraocular cell delivery can be used, that works in the models, and could be used in humans. The procedure is believed to be ~ .
W092~0~06 PCT/US91/08468 15 2 0~ a ~
sufficiently free of complications to be the technique of choice for future transplantation of neural retinal cells into adult hosts.
secause of its technical simplicity and safety, as well as the area of the retina which is covered during lts application, it is believed that procedures in accordance with the invention can be easily and effectively performed in a variety of situations. It is believed that the field of retinal transplantation could benefit from such a safe and reliable means of cell placement.
REFBRENC~
.
1. Lazar and del Cerro M: A new procedure for retinal transplantation, ARVO meeting, Sarasota Florida, May l99O.
Invest. Ophthalmol. Vis. Sci. 31:593, 1990 (Abstr.) 2. del Cerro N, Gash DM, Rao GN, Notter MFD, Wiegand SJ, and Ishida No: Intraocular retinal transplants. ARVO
Meeting, Sarasota, Florida, May, 1984. Invest: Opthalmol Vis. Sci. 25: 62, 1984 (Abstr.) .
I~T}~R13TINA~ DE~ VERY AND WIT}IDR2.WAL IN8TRllM~NTS
BACRGRO~ND AND ~MM~RY OF THE INV~NTION
The invention ls in the field of medlcal devices for intraocular sample delivery and withdrawal. More particularly, it pertains to instruments shaped and ~imensioned for insertion into the orbit along a~ insertion path which extends along the periphery of the eye in a posterior direction to place the instrument tip adjacent to the posterior portions of the eye such as the sclera, choroid, the retina, or vitreous chamber.
Throughout this application various publications and patents are referenced and citations are provided in parentheses for them. The disclosures of these publications in their entireties are hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains.
The remarkable efficiency of the eye as an organ for vision results from its highly specialized organization and the complicated coordination of its component parts which are vital to the process of normal vision. Damage to any essential structure can result in impairment of vision.
Accordingly, it is particularly important that instruments designed for use in or around the eye (ocular globe) to aid in treatment or diagnosis of visual impairment must be safe and reliablej while at the same time permitting access to regions of the eye that are not easily accessible.
A common feature of kncwn prior art intraocular transplantation instruments is that they carry out sample delivery by penetrating an anterior part of the eye, i.e.
via a transcorneal or transcleral route, which crPates the risks of corneal ulceration, cataract formation, and other anterior penetration prob~ems. One exemplary prior art lnstrument is a microspatula which administers cells to the W092/0~06 PCr/~S91/08468 20~6G~6 eye through a trans-scleral or trans-corneal surgical incision (12). Another exemplary prior art instrument is a glass micropipet which replaces cells in the retina by entering the eye anteriorly through an incislon via the scleral route (10). Yet another exemplary instrument is a glass micro canula which effects transplantation of cells into the retina by entering the eye anteriorly through a surgical incisio~ via a trans-scleral or trans-corneal route.
, Known prior art instruments do not directly effect entry into the eye. Instead, an entry portal, i.e. a surgical incision, is believed to be necessary. Surgery involves inherent risks and possi~le complications such as vitreous loss~ cataract formation, and intraocular infection. Of course, any instrument which requires surgical procedures before it could be used is less desirable than instruments which do not. Further, because such prior art instruments effect entry through surgical incisions, any attempts to implant at multiple sites within the eye can be exceedingly difficult and dangerous.
In contrast, the subject invention provides instruments which can entér the eye directly, without reguiring a surgical incision as a prerequisite. Importantly, the subject invention makes it possible to transplant at multiple sites within the eye without the undesirable risks and consequences of multiple surgical procedures.
Further, in contrast to the prior art instruments, the subject invention provides a particularly effective way to control the depth of intraocular penetration. One embodiment of the invention uses a uniquely shaped and positioned adjustable collar to regulate the depth to which the instrument tip may enter the intraocular area. In contrast, it is believed khat known prior art instruments cannot be pre-set to penetrate only to a pre-determined ~'','.
W092/0~0~ PCr/US9~/08468 ~S~Q~ `
desired depth; instead, the penetration depth into the intraocular area is determined at the time of penetration.
These instruments do not have the advantage of effecting intraocular penetration at a predetermined depth. This S feature is believed to be particularly important because the ability to limit the actual penetration depth of -an intraocular instrument could alleviate or eliminate important disorders or symptoms that can be associated with intrusion into the intraocular area. Anothsr important benefit i5 the invention's ability to have a pre-set or predetermined depth of penetration into the eye, is that sample delivery or withdrawal can be pinpo:inted at the desired part of the eye, e.g. only the scleral area, the choroid area, the retinal area, the sub-retinal area, or the vitreous area, etc.
',.
The known prior art instruments typically provide sample delivery but not sample withdrawal with the same instrument~
Further, it is believed that the known prior art instrument cannot be e~fectively pre-set to dispense only a desired volume but rather dispense the sample according to the pressure exerted by, or movement of, the operator at the time of sample delivery, i.e. sample size is not predetermined and dispensed before the instrument is in the eye. Accordingly, prior to the procedure of eye p~netration, there is an effective way to be sure that only a predetermined amount of sample will in fact be administered to or withdrawn from the intraocular area.
.
The invention is believed to provide a new and relîably reproducible means for retinal transplantation without a surgical procedure on the eye as a prerequisite. In contrast, the known literature proposes techniques for intraretinal transplantation which r~quire surgically opening the eye. Lopez, et al. (10) discuss a technique which required making a pars plana incision and inserting a micropipette through the globe into the subretinaI space.
,:. :' ' . ' W092/0~06 PCT/US91/084~8 2 0 ~ 6 4 The method described by Lopez involves forming a retinal detachment in order to properly place the transplant. They note that "there are a number of potential pitfalls associated with this technique" and remark that the host epithelium must first be detached. This is a procedure whlch in the case of the human eye can be associated with subretinal neovascularization. In addit:ion they note that "it may be difficult to be certain that no cells enter the vitreous cavity."
The technique proposed by Sheedlo et al. (ll) rec~ires excision of the superior rectus muscle, followed by an incision into the globe with a blade which penetrate.s the sclera and choroid to expose the subretinal space, prlor to performing the transplantation of cells into this locus.
Following the injection of material, the incision must be closed surgically with suture material.
Silverman and Hughes (12) report a technique which also involves a preliminary ocular incision prior to implantation of tissue. ~hey propose a trans-corneal approach to t~e , .
subretinal space which involves making a transverse incision through the cornea and then traversing the entire gIo~e in order to reach the posterior pole.
BRI~F D~8C~IP~ION OF TH~ p~AWING8 Figure l illustrates a sample delivery and withdrawal instrument in accordance with an exemplary embodiment of the invention.
Figure 2 illustrates access to a posterior portion of the eye using the instrument of Fig. l.
35 ; Figures 3a and 3b illustrate in more detail the tip end of ;;
the instrument of Fig. l and the way the tip is mounted.
',:
: . ., :....
' ' ' ' W092/0~06 PCT/U~91/0~68 2 ~ a ~
Figures 4a and 4b illustrate an alternate way of mounting the instrument tip.
Figure 5 illustrates a prior art technique for rotating the eye so that a posterior portion can be accessed but also illustrates access into a posterior portion of the eye using an instrument tip which can deliver or withdraw a predetermined amount of material in accordance wi~h a feature of the invention.
DBTAI~ED DE8CPcIPTION OF T~IE INVENTION
Referring to Figures 1-4a, an exemplary instrumerlt for withdrawal and delivery of a sample from and to a postPrior part of the eye, has an elongated handle lO having a distal end lOa and a proximal end lOb. Handle 10 is shaped and dimensioned to be grasped by the hand of the user carrying out the procedure of withdrawal or delivery of a sample ~rom or to a posterior part of the eye. The instrument further comprises an elongat~d and curved frame 12 extending ~rom the distal end lOa of handle lO. Frame 12 has a distal end 12a to which a tip 14 is attached. Frame 12, or at least the distal part thereof, and tip 14 are shaped and dimensioned for insertion into an eye orbit along an insertion path (Fig. 2) which extends along the periphery o eye 1~ so as to place tip 14 adjacent to the retina~ or subretinal region 20 and in the direction for penetration into the subretinal region of the eye when said tip ~ is moved generally in the medial direction by manipulating handle 10. A scleral depressor 12c can extend from the distal tip of frame 12, e.g., at an angle of about 4 degrees to each of tip 1~ and the adjacent part of frame 12, away from tip 14, to facilitate insertion of the rame along an insertion path around the periphery of the eye.
Handle 10 and the curved distal Erame 12 can be made of a metal such as titanium, stainless steel, tantalum, or ,,. . .. , : - ., . - .......... , - :. . -, - ~ .
~ : , . ' .... ',: ,. . . : :~ ,. - . : . - : .
, ,: ., .... , , . , - ......... . . . .
. . . - . ... - . ~ . . -W092/0~06 PCT/US9t/~84~
209~ 6 vitallium, or can be made of other suitable materials.
Alternatively, handle 10 and the curved distal frame 12 can be made of a plastic material such as a polyethylene type plastic. Tip 1~ can comprise a needle tip 22 which is made up of a metal such as titanium, stainless steel, tantalum, or vitallium~ or some other suitable material, and an adjustable collar 2~ (Figs. 3a-4b) which regulates the depth to which tip 1~ penetrates the eye, a.g., subretinal region 20 of the eye. Needle tip 22 can be the tip of a needle such as a 30 gauge or a 27 gauge needle, and extends at an angle such as a right angle to the distal end 12a of frame 12. In general, a needle tip in the range from about 32 gauge to 15 gauge would be suitable, depending on the particular patient and procedure, and depending on the physician's preference and needs.
In the example of Figs. 3a and 3b, distal end 12a tapers into a free end terminating into a central opening 12b provided with an internal screw thread mating with an external screw thread 2~a which is at one end of adjustable collar 24. Further, the degree to which needle tip 22 penetrates the eye can be varied by adjusting the extent to which thread 24~ is screwed into thread 12b. In one embodiment o~ the invention, adjustable collar 2~ is a plastic sleeve. In another, it is a metallic adjustable sleeve of the same or similar shape. While it is believed that a sufficient range of penetration depth can be provided only by the degree to which threads 2~ and 12b are screwed into each other, sleeves of different lengths may be used to extend the range. Interchangeable sleeves of different lengths or shapes can be used for other purposes as well, e.g., to accormodate special needs or preferences of the : physician and/or of the patient. Instead o' using mating threads, diff~rent sleeves that snap on or are ~rictionally or otherwise engiaged can be used. As seen in Figs. 4a and 4b, an alternative to the embodiment o~ Figs~ 3a and 3b is to have an internal thxead 2~al at one end of sleeve 24' and ' W092/0~06 PC~/US9l/08~68 7 2~6~6 ~ -an external thread 12b' at the distal end 12a' of the instrument frame.
In order to deliver or withdraw material from the eye, needle tip 22 is hollow and communicates with a passage through frame 1~ which in turn communicates with a passage through handle 10. The passage through handle 10 in turn communicates with a feed line 26 and an aspiration line ~.
Feed line 26 is in selective fluid flow communication with said hollow passage through handle 10 to deliver fluid to the eye through needle tip 22. To effect the del.ivery of a predetermined quantity of ~luid into the eye, a control circuit 30 generates a delivery command signal, e.g., in response to the manual operation of a switch (not shown) to drive a metering pump 32 which pumps into feed line 26 the desired amount of fluid. A fluid supply 34 supplies the fluid to metering pump 32. To aspirate fluid from the eye, aspiration line 28 is in selective ~luid flow commun.ication with a metering vacuum pump 36 which, in response to a similarly generated aspiration command signal from control circuit 38, pumps out the desired quantity of fluid from the eye into a vessel ~0. Of course, if desired, the instrument can be only for delivery of fluid to the eye, or only for aspiration of fluid from the eye, in which case it would have only feed line 26, and the associated components used for fluid delivery, or only aspiration line 28, and its associated components used for aspiration. Feed line 26 and aspiration line 28 can be made up o~ plastic or metal, but plastic feed and aspiration lines are currently preferred.
Referring to Fig. 5, a tip similar to that illustrated in Figs. 3a and 3b, or in Figs. 4a and 4b, which can conveniently regulate the depth of penetration into the eye, can be used in an otherwise prior art technique in accessing a posterior portion of the eye in the illustratPd manner.
W092/0~06 PCT/US91/0~68 2~6~ 8 Various modifications of the disclosed apparatus are possible. For example, while electrically operated and electronically controlled meterlng pumps 32 and 36 can be used as discussed above, in an alternate structure, it is possible to use manually operated, syringe-type delivery and aspiration tools instead.
In an exemplary procedure in accordance with the invention, donor cells were implanted as follows. Second trimester human embryonic retinal cells obtained from electively aborted embryos age 13 to 17 weeks were used as donor tissue. Procurement of donor cells was in accordance with scientific and ethical guidelines which included institutlonal review and approval of the experimental protocol. ~n all cases, maternal consent was given only after the decision to have an elective abortion was made.
The cells were prepared as follows. The eyes were obtained less than one hour after fetal death and collected in either calcium - magnesium medium or in human plasma at 4C.
operating with the aid of a surgical microscope, the eyes were dissected open. The retinas were cleanly cut away, free of contamination from either vitreous or retinal pigment epithelium. Isolated retinas were trimmed into small fragments using a Vannas scissor (Storz, St. Louis, MO), and then placed into ice cold medium. Mechanical dissociation was used to obtain suspension of retinal cells and cell clusters. The dissociation was achieved by aspirating the retinal fragments through butterfly tubing (Abbott Hospitals, North Chicago, Illinois) and then releasing them through the same needle. By varying the needle gauge and ~he number of aspiration ejected cycles it was possible to maintain fine control over the final degree of dissociation. For example, a nearly pure single cell susp nsion lS achieved by 2 cycles through a 30 gauge needle, while 1 cycle through a 27 gauge needle yields a suspension formed by clumps comprising a few hundred cells, as well as a negligible numDer of single cells. Hosts and ' ,: -, '; ' -W092/0~06 PCT/US9l/0~68 9 2 Q ~ 6 anaesthesia were used as follows. Young male adult rats of the Wistar strain served as hosts. In experiments us.ing rats, two to three groups of six rats each were used per experiment. The animals were anaesthetized with a mixture of chloral hydrate and sodium pentobarbi.tal (Chloropent, Henry Schem Inc. Port Washington, NY) at a dose of 3 ml/K~.
Topical 1% Alcaine drops (Propaine Hydrochloride, Alcon, Fort Forth, Texas) were also used as a topical anaesthetic.
The eyes were dilated pre-operatively with one drop each of 1% neo synephrine and 1% mydriacyl (Alcon, Fort Worth, Texas). The following delivery system and transplantation procedure were used. For most experiments, a 27 gauge needle tip, tigh~Iy sheathed in plastic, with 1.2-1.4 mm of the ne~dle tip left exposed, was connected to a microliter syringe (Series 1700, Hamilton, Reno, Nevada), prior to the procedure (Figure 1). The plastic collar placed on the needle serves as an adjustaple regulator. By setting it at the appropriate depth, depending on the animal model being used, the collar serves to limit the depth of penetration and provides protection against over penetration. The plastic collar can be regulated so that only enough of the needle tip is exposed to reach the subretinal space without actually penetrating th~ retina. A major advantage of a tip connected to a pIastic collar during injection into the retinal area is the prevention of large retinal holes or tears. Specifically in this example, minimal over-penetration of the tip causes part of the open portion of the bevel to be in the vitreous area, thereby leading to an intravitreal injection. The microliter syringe was preloaded with A suspension of neuroretinal cells. After the animal was appropriately anesthetized, collibri forceps (Storz, St. Louis, MO) were used to firmly grasp the sclera at the limbus and rotate the globe anteriorly. Then, using a stereo microscope for direct visualization, the needle was manually inserted through the sclera and ~ently rotated until the tip could be directly viewed through the retina, then the tip was advanced further so as to slightly elevate - : , ' ~ :
' ~ ' : ~ `:
W092/0~06 PCT/US91/08468 0 0 ~ 10 the retina. The plastic protective sheath prevents over-penetration of the needle and perforation of the neuroretina. With the bevel of the needle facing the globe, i.e. the ocular globe, the injection of cells was made.
Following the injection, the needle was quickly withdrawn and the procedure repeated at a point 180 degrees opposi~e to the first injection site in the same eye. Typically, two micro-injections were made into the equatorial region of each eye. One was made superiorly at the 12 o'clock position and the other at the 6 o'clock position inferiorly.
However, as many as four penetrations have been performed in a single rat eye and up to six into the lower hemisphere of the monkey eye. The needle was quickly withdrawn following each injection. After the experiment was completed a topical lubricant was placed on the cornea to prevent drying. Control injections were used as follows. In order to obtain instant, permanent and multilevel visuailization of the spread of the injected fluid, colloidal carbon t3,4) was used to perform control injections in the identical manner ~ -as those involving injections of cell suspensions. One group of six animals served as the control group receiving colloidal carbon injections. Colloidal carbon (Biological India Inc., Pelikan, West Germany) was prepared in a 1:4 dilution with saline. In vivo exams were used as follows.
All surgery was performed using an Olympus SZH stereo-microscope fitted with a 35mm photographic camera as well as a videotaping apparatus. The same set up was used to photograph the transplants a~ various stages of growth. For the latter purpose, either a lensing system or a slide was used in order to bring the retina into fine focus. Indirect and direct ophthalmoscopy was routinely performed on all the transplant recipients. Using a Keeler (Keeler, Broomall, Pa) indirect ophthalmoscope and a Volk Pan Retinal lens (Keeler, Broomall, Pa) the animals were examined at regular intervals. This allowed us to constantly monitor the growth and condition of the transplant. Photographs werP taken ,: .
.. ..
W092/0~06 PCT/US9~/08468 through the microscope using a NiXon camera or a Ko~a camera ln conjunction with the indirect ophthalmoscope.
The survival times and histological procedures were as follows. Survival times for the animals receiving cell injections ranged from 3 to 90 post-transplantation days (PTD). Control animals who received injections of coIloidal carbon were sacrificed three days followi~g intraocular injections. The eyes were enucleated, and the animals sacrificed under deep anesthesia using an intramuscular injection of Ketamine 100mg/ml at a dose of 90mg/kg (Quad Pharmaceuticals, Indianapolis, Indiana) and intramuscular Rompun 20mg/ml at a dose of 8mg/kg (Xylazine, Mobay Corp., Shawnee, Kansas). The eyes were enucleated and fixed in 6%
glutaraldehyde in cacodylate bu~fer for 24 to 48 hrs. They were then rinsed in buffer and split along the sagittal axis, extending from the cornea to the optic nerve. The hemisected eyes were examined and photographed under a stereomicroscope, and were then en~edded in plastic ~Eponate 12, Ted Pella, Redding, CA). One micrometer ~m) thick sections were cut and stained with Stevenel Blue (5,6) for light microscopic study. Ultra thin sections were cut with a diamond knife ~or elertron microscopic studies. They wera stained with lead acetate (7) and studied under a Zeiss 10 electron microscope operating at 8~ kilovolts ~Xv). Some of the retinas injected with colloidal carbon were dissected free and prepared as flat-mounts in order to better avaluate the extent of dif~usion of the injected fluid throughout the host retina.
The intraoperative results from the set of control experimen~s using colloidal carbon, demonstrated that the carbon is injected precisely into the sub-retinal space.
The entire procedure could be viewed directly under the operating microscope. It was possible to see how the needle penetrated the sclera and pushed the retina upward. At that point, the bevel was turned in order to put it in apposition :
W092/0~06 PCT/~'S91/08468 '~9~0~)~ 12 to the retina, at an orientation which assured proper localization of the injected material. At this point, the injection was carried out. As the two microliters of fluid were injected, the colloidal carbon was readily seen spreading over the retinal surface. The material quickly fanned out and covered anywhere from 60 to l80 ~er injection. The colloidal carbon dramatically illustrate$
the wide diffusion of the injected fluid over the surface of the host retina. It also serves as a control for the results obtained by transplanting living cells. Access to any portion of the retina, even as far poster:iorly as the region around the optic nerve head, was possible.
Clinical observations have confirmed the atraumatic nature of this techniqueO The wound is s~lf-sealing, thus requiring no surgical closure. There was no vitreal loss at the time of injection and post operative examinations showed no corneal opacities, no lenticular changes, a nor~al optic nerve head, and an intra-ocular pressure which remained stable throughout. Indirect ophthalmoscopy was negative for signs of hemorrhage, neo-vasculari2ation, uveitis or ocular -`
infection in the eyes of approximately l00 rats and 2 monkeys transplanted using this procedure.
Histological observations correlated well wlth those made by biomicroscQpy. Sections of eyes injected with a tracer and those injected with suspensions of living human fetal retinal cells showed considerable dispersion of the injected material, which spread onto the outer retinal surface from the subretinal injection point. Colloidal carbon injections dramatically illustrate the vast surface of the host retina which is covered by even a single injection. When a flat mount is made of the same preparation, it dramatically indicates the wide diffusion of the carbon granules throughout the retina. On histological specimens involving colloidal carbon injecti4ns, there is clearly intraretinal colloidal carbon materials scattered throughout.
~':
, W092/0~06 PCT/US91/08468 13 ~t~ 8 In experiments where living human fetal retinal cells were grafted, the same pattern of distribution was observed as 7 those seen in control injections, where colloidal c~rbon was introduced into the subretlnal space. Typically, the penetration point was marked by comparatively large clusters of cells, which could reach dimensions of 250 micrometers thick and 600 micrometers wide.
The initial retinal transplantation experime1lts (8) were performed using glass micropipettes attached to a microliter syringe. A preliminary incision was made through the sclera, and the transplant was then perfo~med. This technique, although very effective in the rodent model, proved to be difficult and time consuming with severe limitations on accuracy. Suturing of the minute incision in particular, was associated with a sharp increase in complications, such as retinal detachments subretinal hemorrhages, and formation of intravitreal membranes. A
modified approach was developed which avoided suturing (9) and its complications, e.g. decreased the formation of pre-retinal membranes, and sharply reduced the incidence of hemorrhaging. However, the method did not eliminate the associated problems in their entirety. Therefore, a need for devising a more expeditious and efficient means of transplantation became necessary, i.e. a method that would make multi site grafting into retinas not only possible, but virtually free from surgical complications. It i5 believed that a quick and atraumatic method could limit the complications, as well as the cellular response. A goal was to formulate a means which would be uncomplicated and quick, but at the same time guarantee that the cells would be delivered intraretinally, at multiple points, in a safe and reliable manner.
The closed eye method of transplantation is believed to be hi~hly ~esirable because it avoids the need for surgically W092/0~06 PCT/US91/08468 opening the eye and thus makes it feasible and practical to perform multiple simultaneous grafts into an intact globe.
The procedures, in accordance with the invention, have photographically demonstrated a retinal transplantation.
The methods have undergonP sufficient laboratory testlng ~o state that the cells are being delivered at the desired subretinal or intraretinal locations under direct visual control by the operator.
The procedure, in accordance with the invention, is believed o be quick and efficient and to provide the added advantage of multi-site delivery of cells over a broad surface area, and thereby to vastly improve the odds for success of the transplantation. Perhaps even more significantly, it is a benign proce~ure. Because it is quick, there is only a need for brief anaesthesia, to thereby further limit the complication rate. The rapid transplantation of cells also diminishes the risk of infection or post-operative complications. The simplicity of the procedure, an intraocular injection, means that the risk of intraoperative complication should be minimal. The rat model presents an uncomplicated approach. In all the cases performed by or for the rodent and primates (13) there have been no intra-operative or post-operative-complications.
When performing these procedures, it is desirable to use different parameters in order to test various experimental paradigms. By allowing controlled penetration of the sub-retinal and retinal spaces this technique does exactly that.
The colloidal carbon manifests precise placement o~ material on a macroscopic and histological level. When using living donor cells, the results shown by histo}ogical examination are once again the same successful intraretinal placement of cells. The results, in accordance with the invention, sugyest that a reproducible procedure of intraocular cell delivery can be used, that works in the models, and could be used in humans. The procedure is believed to be ~ .
W092~0~06 PCT/US91/08468 15 2 0~ a ~
sufficiently free of complications to be the technique of choice for future transplantation of neural retinal cells into adult hosts.
secause of its technical simplicity and safety, as well as the area of the retina which is covered during lts application, it is believed that procedures in accordance with the invention can be easily and effectively performed in a variety of situations. It is believed that the field of retinal transplantation could benefit from such a safe and reliable means of cell placement.
REFBRENC~
.
1. Lazar and del Cerro M: A new procedure for retinal transplantation, ARVO meeting, Sarasota Florida, May l99O.
Invest. Ophthalmol. Vis. Sci. 31:593, 1990 (Abstr.) 2. del Cerro N, Gash DM, Rao GN, Notter MFD, Wiegand SJ, and Ishida No: Intraocular retinal transplants. ARVO
Meeting, Sarasota, Florida, May, 1984. Invest: Opthalmol Vis. Sci. 25: 62, 1984 (Abstr.) .
3. del Cerro M, Grover DA, Dematte JE, and Williams, WM: Colloidal carbon as a combined ophthalmoscopic and microscopic probe of the retinal-blood barrier integrity.
Ophthalmic Res . 17: 34, 1385.
Ophthalmic Res . 17: 34, 1385.
4. Triarhou L. and del Cerro M: Colloi~al càrbon as a multilevel marker for experimental lesions. Experientia 41;
620,1985.
:
620,1985.
:
5. del Cerro M, Cogen M~Jo ~ and del Cerr~ C: ~n excellent stain for opticalmicroscopy study of plastic embedded tissues. Microscope Acta i33: 5453, }980.
. ' ~ .
:
: .~ , .~ , ~ .-,: :, . - . , . , , , , , . . . : : . . : . : . . , :
WO92/0~Q6 PCT/US~1/08468 2a~5~ 16 6. del Cerro M, Standler M, and del Cerro C: High resolution optical microscopy of animal tissues by the use of sub-micrometer thick sections and a new stain. Microscope Acta 83: 117, 1980.
. ' ~ .
:
: .~ , .~ , ~ .-,: :, . - . , . , , , , , . . . : : . . : . : . . , :
WO92/0~Q6 PCT/US~1/08468 2a~5~ 16 6. del Cerro M, Standler M, and del Cerro C: High resolution optical microscopy of animal tissues by the use of sub-micrometer thick sections and a new stain. Microscope Acta 83: 117, 1980.
7. Venable, ~. and Cogeshall R: A simplified lead citrate stain for use in electron microC,copy. J. Cell Biol.
407, 19~5.
407, 19~5.
8. del Cerro M, Gash D.M., Notter M, Rao G.No, Wiegand S, Jiang L, and del Cerro C: Transplanting strips of immature retinal tissue and suspensions of dissociated retinal cells into normal and ~xtensively damaged eyes. Ann of N.Y. Acad of Sci 495: 692, 1986.
9. del Cerro M, Notter M, del Cerro C, Wiegand S, Grover D, and Lazer E (1989) Intraretinal Transplantation for rod-cell replacement in light-damaged retinas. J o~
Neur. Transpl. 1:1.
Neur. Transpl. 1:1.
10. Lopez R, Gouras P, Brittis M, and Kjeldby H;
Transplantation of cultured rabbit retinal epithelium to ~`~
rabbit retina using a closed eye method, Invest Opthalmol Vis Sci 28: 1131, l9A7 11. Sheedlo H, Li L, and Turner J: Functio~al and structural characteristic of photoreceptor cells rescued in RPE- cell grafted retinas of RCS dystrophic rats. Exp. Eye Res. 48:841, 1989.
Transplantation of cultured rabbit retinal epithelium to ~`~
rabbit retina using a closed eye method, Invest Opthalmol Vis Sci 28: 1131, l9A7 11. Sheedlo H, Li L, and Turner J: Functio~al and structural characteristic of photoreceptor cells rescued in RPE- cell grafted retinas of RCS dystrophic rats. Exp. Eye Res. 48:841, 1989.
12. 5ilverman M, and Hughes, S: Transplantation of Pho oreceptors to Light-Damaged Retina. Invest Ophthalmol Vis Sci. 30: 1684, 1989.
~: .
~: .
13. del Cerro M, Lazar E, Grover D, Gallagher M, Sladek C, Chu J~ and del Cerro C: Intraocular Transplantation and culture of human embryonic retinal , :. ',:
,,'`:
~ . : .. .
: ,'.
.. . ~ .. .. . .. . .. . . . . . . ... , . . . . . ~ . ... .
17 2~ 6~ ~
cells. ARVO meeting, Sarasota Florida, May l990. Invest Ophthalmol. Vis. Sci. 31: 593, l990 (Abstr.) :
:
~ . ' . ~ , ,: .
,,'`:
~ . : .. .
: ,'.
.. . ~ .. .. . .. . .. . . . . . . ... , . . . . . ~ . ... .
17 2~ 6~ ~
cells. ARVO meeting, Sarasota Florida, May l990. Invest Ophthalmol. Vis. Sci. 31: 593, l990 (Abstr.) :
:
~ . ' . ~ , ,: .
Claims (18)
1. An intraocular delivery and withdrawal instrument comprising:
an elongated handle having a distal end and a proximal end and shaped and dimensioned to be grasped by the hand of a user and an elongated curved frame extending from the distal end of the handle and having a proximal end; and a tip extending from said distal end of the frame;
said frame and tip being shaped and dimensioned for insertion into an orbit along an insertion path around the periphery of the eye so to place said tip adjacent to the retina and pointing in a direction for penetration into the intraocular region of the eye when said tip is moved generally in the medial direction by manipulating said handle.
an elongated handle having a distal end and a proximal end and shaped and dimensioned to be grasped by the hand of a user and an elongated curved frame extending from the distal end of the handle and having a proximal end; and a tip extending from said distal end of the frame;
said frame and tip being shaped and dimensioned for insertion into an orbit along an insertion path around the periphery of the eye so to place said tip adjacent to the retina and pointing in a direction for penetration into the intraocular region of the eye when said tip is moved generally in the medial direction by manipulating said handle.
2. An instrument as in claim 1 including an adjustable collar secured to the instrument to regulate the extent to which said tip penetrates into the intraocular region of the eye.
3. An instrument as in claim 2 in which said tip comprises a 30 gauge needle tip extending at an angle to the distal end of said frame.
4. An instrument as in claim 2 in which said tip comprises a 27 gauge needle tip extending at an angle to the distal end of said frame.
5. An instrument as in claim 2 in which said tip comprises a screw thread and said adjustable collar and has a mating screw thread to allow varying said degree of penetration by the degree to which said screw threads mate.
6. An instrument as in claim 5 in which said adjustable collar is made of a plastic material.
7. An instrument as in claim 5 in which said adjustable collar is made of a metal.
8. A method for grafting cells into an intraretinal eye area which comprises:
inserting the instrument of claim 1 into the retinal area of the eye generally in the medial direction; and transferring cells from the instrument into said retinal area to thereby graft the cells into the intraocular eye area.
inserting the instrument of claim 1 into the retinal area of the eye generally in the medial direction; and transferring cells from the instrument into said retinal area to thereby graft the cells into the intraocular eye area.
9. A method for delivering a solution to an intraretinal area of an eye in vivo which comprises:
inserting an intraocular delivery and withdrawal instrument into an orbit in an insertion direction which is peripheral to the eye and within the orbit; said instrument comprising an elongated handle having a distal end and a proximal end and shaped and dimensioned to be grasped by the hand of a user and an elongated curved frame extending from the distal end of the handle and having a proximal end; and a tip extending from said distal end of the frame; said frame and tip being shaped and dimensioned for insertion into said orbit in said insertion direction so to place said tip adjacent to the retina and pointing in a direction for penetration into the intraocular region of the eye when said tip is moved generally in the medial direction by manipulating said handle;
penetrating the intraocular area with said tip generally in the medial direction; and transferring solution from the instrument to the intraocular area.
inserting an intraocular delivery and withdrawal instrument into an orbit in an insertion direction which is peripheral to the eye and within the orbit; said instrument comprising an elongated handle having a distal end and a proximal end and shaped and dimensioned to be grasped by the hand of a user and an elongated curved frame extending from the distal end of the handle and having a proximal end; and a tip extending from said distal end of the frame; said frame and tip being shaped and dimensioned for insertion into said orbit in said insertion direction so to place said tip adjacent to the retina and pointing in a direction for penetration into the intraocular region of the eye when said tip is moved generally in the medial direction by manipulating said handle;
penetrating the intraocular area with said tip generally in the medial direction; and transferring solution from the instrument to the intraocular area.
10. A method of claim 9 in which said solution is a pharmaceutical agent.
11. A method of claim 9, wherein the solution is a toxin.
12. A method for withdrawing a biological sample from an intraocular area of an eye in vivo which comprises:
inserting an intraocular delivery and withdrawal instrument comprising an elongated handle having a distal end and a proximal end and shaped and dimensioned to be grasped by the hand of a user and an elongated curved frame extending from the distal end of the handle and having a proximal end; and a tip extending from said distal end of the frame; said frame and tip being shaped and dimensioned for insertion into an orbit along an insertion path around the periphery of the eye so to place said tip adjacent to the retina and pointing in a direction or penetration into the intraocular region of the eye when said tip is moved generally in the medial direction by manipulating said handle; into an orbit in an insertion direction around the periphery of the eye and penetrating the eye generally in the medial direction so as to reach the intraocular area with said tip; and transferring a sample from the intraocular area to the instrument and withdrawing said instrument from the eye.
inserting an intraocular delivery and withdrawal instrument comprising an elongated handle having a distal end and a proximal end and shaped and dimensioned to be grasped by the hand of a user and an elongated curved frame extending from the distal end of the handle and having a proximal end; and a tip extending from said distal end of the frame; said frame and tip being shaped and dimensioned for insertion into an orbit along an insertion path around the periphery of the eye so to place said tip adjacent to the retina and pointing in a direction or penetration into the intraocular region of the eye when said tip is moved generally in the medial direction by manipulating said handle; into an orbit in an insertion direction around the periphery of the eye and penetrating the eye generally in the medial direction so as to reach the intraocular area with said tip; and transferring a sample from the intraocular area to the instrument and withdrawing said instrument from the eye.
13. A method as in claim 12 in which said biological sample is a cell.
14. A method as in claim 12 in which said biological sample is intraocular fluid.
15. An intraocular delivery and/or withdrawal instrument comprising:
an elongated handle having a distal end and a proximal end and shaped and dimensioned to be grasped by the hand of a user;
an elongated and curved frame extending from the distal end of the handle and having a distal end;
and a tip having a hollow passage therein and extending from said distal end of the frame;
said frame and tip being shaped and dimensioned for insertion into an orbit along an insertion path around the periphery of the eye so as to place said tip adjacent the retina and pointing in the medial direction for penetrating into the intraocular region of the eye upon further manipulation of said instrument; and at least one of:
(i) a feed line which is in selective fluid flow communication with said hollow passage of the tip to deliver material thereto, means for selectively generating a delivery command signal and means responsive to said delivery command signal to deliver a selected quantity of a selected material to said hollow passage; and (ii) an aspiration line which is in selective fluid flow communication with said hollow passage of the tip to aspirate material therefrom, means for selectively generating an aspiration command signal and means responsive to said aspiration command signal to aspirate a selected quantity of material from said hollow passage.
an elongated handle having a distal end and a proximal end and shaped and dimensioned to be grasped by the hand of a user;
an elongated and curved frame extending from the distal end of the handle and having a distal end;
and a tip having a hollow passage therein and extending from said distal end of the frame;
said frame and tip being shaped and dimensioned for insertion into an orbit along an insertion path around the periphery of the eye so as to place said tip adjacent the retina and pointing in the medial direction for penetrating into the intraocular region of the eye upon further manipulation of said instrument; and at least one of:
(i) a feed line which is in selective fluid flow communication with said hollow passage of the tip to deliver material thereto, means for selectively generating a delivery command signal and means responsive to said delivery command signal to deliver a selected quantity of a selected material to said hollow passage; and (ii) an aspiration line which is in selective fluid flow communication with said hollow passage of the tip to aspirate material therefrom, means for selectively generating an aspiration command signal and means responsive to said aspiration command signal to aspirate a selected quantity of material from said hollow passage.
16. An instrument as in claim 15 including both elements (i) and (ii).
17. An instrument as in claim 15 having only element (i) and being free of element (ii).
18. An instrument as in claim 15 having only element (ii) and being free of element (i).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US613,165 | 1990-11-14 | ||
US07/613,165 US5273530A (en) | 1990-11-14 | 1990-11-14 | Intraretinal delivery and withdrawal instruments |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2096006A1 true CA2096006A1 (en) | 1992-05-15 |
Family
ID=24456138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002096006A Abandoned CA2096006A1 (en) | 1990-11-14 | 1991-11-13 | Intraretinal delivery and withdrawal instruments |
Country Status (6)
Country | Link |
---|---|
US (2) | US5273530A (en) |
EP (1) | EP0557445A1 (en) |
JP (1) | JPH06505647A (en) |
AU (1) | AU9062891A (en) |
CA (1) | CA2096006A1 (en) |
WO (1) | WO1992008406A1 (en) |
Families Citing this family (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817075A (en) * | 1989-08-14 | 1998-10-06 | Photogenesis, Inc. | Method for preparation and transplantation of planar implants and surgical instrument therefor |
SG49267A1 (en) | 1989-08-14 | 1998-05-18 | Photogenesis Inc | Surgical instrument and cell isolation and transplantation |
US6045791A (en) * | 1992-03-06 | 2000-04-04 | Photogenesis, Inc. | Retinal pigment epithelium transplantation |
JPH09501065A (en) * | 1993-03-16 | 1997-02-04 | フォトジェネシス インコーポレイテッド | Spiral implant preparation and implantation method and surgical instrument therefor |
US5868728A (en) * | 1995-02-28 | 1999-02-09 | Photogenesis, Inc. | Medical linear actuator for surgical delivery, manipulation, and extraction |
US5827216A (en) | 1995-06-07 | 1998-10-27 | Cormedics Corp. | Method and apparatus for accessing the pericardial space |
US5910139A (en) * | 1996-08-29 | 1999-06-08 | Storz Instrument Co. | Numeric keypad simulated on touchscreen |
US6251113B1 (en) | 1996-08-29 | 2001-06-26 | Bausch & Lomb Surgical, Inc. | Ophthalmic microsurgical system employing surgical module employing flash EEPROM and reprogrammable modules |
US6117126A (en) * | 1996-08-29 | 2000-09-12 | Bausch & Lomb Surgical, Inc. | Surgical module with independent microprocessor-based communication |
US5997528A (en) * | 1996-08-29 | 1999-12-07 | Bausch & Lomb Surgical, Inc. | Surgical system providing automatic reconfiguration |
US6086576A (en) * | 1996-08-29 | 2000-07-11 | Bausch & Lomb Surgical, Inc. | Automatically switching the termination of a communications bus |
JP3022389B2 (en) * | 1997-03-14 | 2000-03-21 | 株式会社イナミ | Membrane eraser |
US6051011A (en) * | 1997-08-28 | 2000-04-18 | Bausch & Lomb Surgical, Inc. | Surgical handpiece |
US6055458A (en) * | 1997-08-28 | 2000-04-25 | Bausch & Lomb Surgical, Inc. | Modes/surgical functions |
AU765034B2 (en) * | 1998-07-06 | 2003-09-04 | Robert E Morris | Method and apparatus for performing surgery inside the human retina using fluidic internal limiting membrane (ILM) separation (films) |
US6024719A (en) * | 1998-07-06 | 2000-02-15 | Morris; Robert E | Method and apparatus for performing surgery inside the human retina using fluidic internal limiting membrane (ILM) seperation (FILMS) |
US6309374B1 (en) | 1998-08-03 | 2001-10-30 | Insite Vision Incorporated | Injection apparatus and method of using same |
US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
KR100312659B1 (en) * | 1998-09-18 | 2002-02-19 | 하권익 | Syringe for lower retina |
EP1154691A4 (en) * | 1999-01-05 | 2004-07-07 | Massachusetts Eye & Ear Infirm | Targeted transscleral controlled release drug delivery to the retina and choroid |
US6389317B1 (en) * | 2000-03-31 | 2002-05-14 | Optobionics Corporation | Multi-phasic microphotodetector retinal implant with variable voltage and current capability |
US20040039401A1 (en) * | 2000-03-31 | 2004-02-26 | Chow Alan Y. | Implant instrument |
US7867186B2 (en) | 2002-04-08 | 2011-01-11 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
US6638239B1 (en) | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
US20030171722A1 (en) * | 2001-01-04 | 2003-09-11 | Michel Paques | Microsurgical injection and/or distending instruments and surgical method and apparatus utilizing same |
US7122042B2 (en) * | 2001-03-15 | 2006-10-17 | Lorusso Frank J | Apparatuses and methods for transcleral cautery and subretinal drainage |
CA2683224C (en) | 2001-04-07 | 2014-12-02 | Glaukos Corporation | System and methods thereof for treatment of ocular disorders |
US7037943B2 (en) | 2001-04-10 | 2006-05-02 | Optobionics Corporation | Retinal treatment method |
US7795218B2 (en) | 2001-04-12 | 2010-09-14 | Bioaxone Therapeutique Inc. | ADP-ribosyl transferase fusion variant proteins |
WO2002089767A1 (en) | 2001-05-03 | 2002-11-14 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
US7485113B2 (en) * | 2001-06-22 | 2009-02-03 | Johns Hopkins University | Method for drug delivery through the vitreous humor |
US7331984B2 (en) | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
KR100431454B1 (en) * | 2001-10-15 | 2004-05-14 | 사회복지법인삼성생명공익재단(삼성서울병원) | Injector under The Retina |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
WO2003092665A2 (en) * | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
FR2839454A1 (en) * | 2002-05-07 | 2003-11-14 | Primebiotech | DEVICE FOR MICRO-INJECTION OF LIQUID IN A CONFINED MEDIUM |
US7699882B2 (en) * | 2002-09-17 | 2010-04-20 | Iscience Interventional Corporation | Apparatus and method for surgical bypass of aqueous humor |
AU2003279055A1 (en) * | 2002-09-29 | 2004-04-19 | Surmodics, Inc. | Methods for treatment and/or prevention of retinal disease |
WO2004073551A2 (en) * | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
US20040199130A1 (en) * | 2003-04-03 | 2004-10-07 | Chornenky Victor I. | Apparatus and method for treatment of macular degeneration |
CN1950124B (en) * | 2004-01-12 | 2010-11-10 | Ⅰ科学外科公司 | Injector for viscous materials |
CN1976732A (en) * | 2004-04-29 | 2007-06-06 | i科学外科公司 | Apparatus and method for surgical enhancement of aqueous humor drainage |
US20100173866A1 (en) * | 2004-04-29 | 2010-07-08 | Iscience Interventional Corporation | Apparatus and method for ocular treatment |
WO2006014484A2 (en) * | 2004-07-02 | 2006-02-09 | Surmodics, Inc. | Methods and devices for the treatment of ocular conditions |
JP2008535847A (en) | 2005-04-08 | 2008-09-04 | サーモディクス,インコーポレイティド | Sustained release implant for subretinal delivery |
US20070005016A1 (en) * | 2005-06-20 | 2007-01-04 | Williams David F | Ocular injection device and method |
US8591457B2 (en) * | 2005-08-10 | 2013-11-26 | Alza Corporation | Method for making a needle-free jet injection drug delivery device |
JP4358821B2 (en) * | 2005-12-15 | 2009-11-04 | オリンパス株式会社 | Intra-subject introduction device |
US7544371B2 (en) * | 2005-12-20 | 2009-06-09 | Bausch + Lomb Incorporated | Drug delivery systems |
US20070148244A1 (en) * | 2005-12-22 | 2007-06-28 | Kunzler Jay F | Drug delivery systems |
US20070202186A1 (en) * | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
US20070218103A1 (en) * | 2006-03-15 | 2007-09-20 | Bausch & Lomb Incorporated | Rate controlled release of a pharmaceutical agent in a biodegradable device |
US20070218104A1 (en) * | 2006-03-15 | 2007-09-20 | Bausch & Lomb Incorporation | Rate controlled release of a pharmaceutical agent in a biodegradable device |
US8663303B2 (en) | 2010-11-15 | 2014-03-04 | Aquesys, Inc. | Methods for deploying an intraocular shunt from a deployment device and into an eye |
US7579021B2 (en) | 2006-09-27 | 2009-08-25 | Bausch & Lomb Incorporated | Drug delivery systems based on degradable cationic siloxanyl macromonomers |
EP2088976B1 (en) | 2006-11-10 | 2019-07-03 | Glaukos Corporation | Uveoscleral shunt |
US20080145405A1 (en) * | 2006-12-15 | 2008-06-19 | Kunzler Jay F | Drug delivery devices |
US20100152646A1 (en) * | 2008-02-29 | 2010-06-17 | Reshma Girijavallabhan | Intravitreal injection device and method |
EP2262555A2 (en) * | 2008-03-27 | 2010-12-22 | iScience Interventional Corporation | Microliter injector |
US8425473B2 (en) | 2009-01-23 | 2013-04-23 | Iscience Interventional Corporation | Subretinal access device |
US20100191177A1 (en) * | 2009-01-23 | 2010-07-29 | Iscience Interventional Corporation | Device for aspirating fluids |
US9198797B2 (en) | 2009-09-22 | 2015-12-01 | Doheny Eye Institute | Adjustable cannula systems and devices |
CN105435338B (en) | 2010-08-05 | 2019-03-26 | 弗赛特影像4股份有限公司 | Injector apparatus and method for drug conveying |
EP3520749A1 (en) | 2010-10-15 | 2019-08-07 | Clearside Biomedical, Inc. | Device for ocular access |
US20160256317A1 (en) | 2010-11-15 | 2016-09-08 | Aquesys, Inc. | Methods for implanting intraocular shunts |
WO2012073180A1 (en) * | 2010-12-02 | 2012-06-07 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Subretinal delivery of therapeutic compositions |
EP4249059A3 (en) | 2011-06-28 | 2023-11-29 | ForSight Vision4, Inc. | An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye |
DK3290024T3 (en) | 2011-08-29 | 2019-06-03 | Mati Therapeutics Inc | CONTINUING SUBMISSION OF ACTIVE RESOURCES FOR TREATMENT OF GLAUCUM AND OCULAR HYPERTENSION |
SI2755600T1 (en) | 2011-09-16 | 2021-08-31 | Forsight Vision4, Inc. | Fluid exchange apparatus |
US9370447B2 (en) * | 2011-10-10 | 2016-06-21 | Cygnus LP | Probes for use in ophthalmic and vitreoretinal surgery |
US9808373B2 (en) | 2013-06-28 | 2017-11-07 | Aquesys, Inc. | Intraocular shunt implantation |
US9282995B2 (en) | 2011-12-22 | 2016-03-15 | Previvo Genetics, Llc | Recovery and processing of human embryos formed in vivo |
US20150272622A1 (en) | 2011-12-22 | 2015-10-01 | Previvo Genetics, Llc | Recovery and processing of human embryos formed in vivo |
US9216037B2 (en) | 2013-06-21 | 2015-12-22 | Previvo Genetics, Llc | Uterine lavage for embryo retrieval |
WO2013148275A2 (en) | 2012-03-26 | 2013-10-03 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US9335455B2 (en) | 2012-05-30 | 2016-05-10 | Cygnus, LP | Extended tip laser and illumination probe for retina surgery |
US9757536B2 (en) | 2012-07-17 | 2017-09-12 | Novartis Ag | Soft tip cannula |
CA2882184C (en) * | 2012-08-27 | 2021-09-07 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using microneedles |
US9795508B2 (en) * | 2012-11-06 | 2017-10-24 | Alcon Research, Ltd. | Ocular infusion system |
CA2890471C (en) | 2012-11-08 | 2021-07-27 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
SG10201702674PA (en) | 2013-05-03 | 2017-06-29 | Clearside Biomedical Inc | Apparatus and methods for ocular injection |
EP3003454B1 (en) | 2013-06-03 | 2020-01-08 | Clearside Biomedical, Inc. | Apparatus for drug delivery using multiple reservoirs |
EP3068354B1 (en) * | 2013-11-14 | 2023-06-28 | Aquesys, Inc. | Intraocular shunt inserter |
US10010447B2 (en) | 2013-12-18 | 2018-07-03 | Novartis Ag | Systems and methods for subretinal delivery of therapeutic agents |
US9730834B2 (en) | 2013-12-20 | 2017-08-15 | Novartis Ag | Variable stiffness cannula and methods for a surgical system |
PT3104814T (en) | 2014-02-12 | 2021-06-17 | Gyroscope Therapeutics Ltd | Method and apparatus for suprachoroidal administration of therapeutic agent |
US9949874B2 (en) | 2014-06-06 | 2018-04-24 | Janssen Biotech, Inc. | Therapeutic agent delivery device with convergent lumen |
US9925088B2 (en) | 2014-06-06 | 2018-03-27 | Janssen Biotech, Inc. | Sub-retinal tangential needle catheter guide and introducer |
CA2952958A1 (en) | 2014-06-20 | 2015-12-23 | Clearside Biomedical, Inc. | Variable diameter cannula and methods for controlling insertion depth for medicament delivery |
US9895261B1 (en) * | 2014-07-03 | 2018-02-20 | Ahmad Bakir Tarabishy | Device and method for treating retinal detachment |
US9999542B2 (en) | 2014-07-16 | 2018-06-19 | Doheny Eye Institute | Systems, methods, and devices for cannula insertion |
US10258502B2 (en) | 2014-09-18 | 2019-04-16 | Orbit Biomedical Limited | Therapeutic agent delivery device |
CN104688418A (en) * | 2015-04-03 | 2015-06-10 | 苏州贝尔一锋医疗器械有限公司 | Restorer |
WO2017139375A1 (en) | 2016-02-10 | 2017-08-17 | Clearside Biomedical, Inc. | Ocular injection kit, packaging, and methods of use |
US10251634B2 (en) * | 2016-02-19 | 2019-04-09 | Brett Foxman | Scleral depressor |
US10478553B2 (en) | 2016-03-09 | 2019-11-19 | Orbit Biomedical Limited | Apparatus for subretinal administration of therapeutic agent via a curved needle |
JP2019514581A (en) | 2016-05-02 | 2019-06-06 | クリアサイド バイオメディカル,インコーポレイテッド | Systems and methods for ocular drug delivery |
CA3025526A1 (en) | 2016-06-02 | 2017-12-07 | Aquesys, Inc. | Intraocular drug delivery |
CN110177527B (en) | 2016-08-12 | 2022-02-01 | 科尼尔赛德生物医学公司 | Device and method for adjusting insertion depth of needle for medicament delivery |
KR20190061047A (en) | 2016-09-30 | 2019-06-04 | 마티 테라퓨틱스 인코포레이티드 | Slow release formulation of ophthalmic drug and its use |
EP3554435A4 (en) * | 2016-12-15 | 2020-07-01 | Clearside Biomedical, Inc. | Systems and methods for delivering drugs to retinal tissue |
US11273072B2 (en) | 2017-01-13 | 2022-03-15 | Gyroscope Therapeutics Limited | Suprachoroidal injection device |
US11076984B2 (en) | 2017-03-13 | 2021-08-03 | Gyroscope Therapeutics Limited | Method of performing subretinal drainage and agent delivery |
US11439772B2 (en) * | 2017-03-17 | 2022-09-13 | Jasperate, Inc. | Hollow needle for access in non-linear path |
EP3691586A2 (en) | 2017-10-06 | 2020-08-12 | Glaukos Corporation | Systems and methods for delivering multiple ocular implants |
USD846738S1 (en) | 2017-10-27 | 2019-04-23 | Glaukos Corporation | Implant delivery apparatus |
US11246753B2 (en) | 2017-11-08 | 2022-02-15 | Aquesys, Inc. | Manually adjustable intraocular flow regulation |
WO2019103906A1 (en) | 2017-11-21 | 2019-05-31 | Forsight Vision4, Inc. | Fluid exchange apparatus for expandable port delivery system and methods of use |
US11135089B2 (en) | 2018-03-09 | 2021-10-05 | Aquesys, Inc. | Intraocular shunt inserter |
US11759355B1 (en) | 2019-02-26 | 2023-09-19 | Gyroscope Therapeutics Limited | Method of delivering leading blebs and agent to subretinal space |
CN113069273B (en) * | 2021-03-30 | 2023-01-03 | 西安市人民医院(西安市第四医院) | Retinal fissure hole scleral surface positioning and subretinal fluid drainage device |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE496458A (en) * | ||||
US1125887A (en) * | 1914-04-08 | 1915-01-19 | Gustav R Schimmel | Hypodermic syringe. |
US2923295A (en) * | 1958-05-22 | 1960-02-02 | Federico D C Guerriero | Cannula-directed hypodermic needle |
US3636940A (en) * | 1967-12-07 | 1972-01-25 | Leland C Gravlee | Method for collecting cellular material by circulating a fluid within a body cavity |
US3735751A (en) * | 1971-06-08 | 1973-05-29 | S Katz | Lavage and cytology instrument |
US3957035A (en) * | 1972-09-08 | 1976-05-18 | Jean Chassaing | Ophthalmological device useful for eye surgery |
US3982541A (en) * | 1974-07-29 | 1976-09-28 | Esperance Jr Francis A L | Eye surgical instrument |
GB1577645A (en) * | 1977-02-21 | 1980-10-29 | Novo Lab Inc | Apparatus for introducing a predetermined volume of enzyme solution into the lens of an eye |
FR2461002A1 (en) * | 1979-07-13 | 1981-01-30 | Inst Nat Sante Rech Med | METHOD FOR STIMULATING THE GROWTH OF HUMAN EPIDERMIC CELLS AND PRODUCTS USING THE SAME |
SU1052232A1 (en) * | 1981-02-27 | 1983-11-07 | Московская Научно-Исследовательская Лаборатория Экспериментальной И Клинической Хирургии Глаза С Клиникой | Apparatus for ophthalmologic surgery |
US4692142A (en) * | 1986-02-24 | 1987-09-08 | Dignam Bernard J | Sutureless infusion cannula for ophthalmic surgery |
US4714464A (en) * | 1986-10-27 | 1987-12-22 | Entravision, Inc. | Mechanism for coupling the aspirant line of an irrigation/aspiration machine to the pressure monitoring section |
US4744360A (en) * | 1986-12-18 | 1988-05-17 | Bath Patricia E | Apparatus for ablating and removing cataract lenses |
US4759746A (en) * | 1987-05-14 | 1988-07-26 | Straus Jeffrey G | Retro-bulbar needle |
DE69032100T2 (en) * | 1989-08-14 | 1998-10-29 | Photogenesis Inc | SURGICAL INSTRUMENT AND CELL INSULATION |
-
1990
- 1990-11-14 US US07/613,165 patent/US5273530A/en not_active Expired - Fee Related
-
1991
- 1991-11-13 AU AU90628/91A patent/AU9062891A/en not_active Abandoned
- 1991-11-13 JP JP4502282A patent/JPH06505647A/en active Pending
- 1991-11-13 CA CA002096006A patent/CA2096006A1/en not_active Abandoned
- 1991-11-13 WO PCT/US1991/008468 patent/WO1992008406A1/en not_active Application Discontinuation
- 1991-11-13 EP EP92901184A patent/EP0557445A1/en not_active Ceased
-
1993
- 1993-12-21 US US08/171,004 patent/US5409457A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU9062891A (en) | 1992-06-11 |
WO1992008406A1 (en) | 1992-05-29 |
US5273530A (en) | 1993-12-28 |
EP0557445A1 (en) | 1993-09-01 |
EP0557445A4 (en) | 1994-01-19 |
JPH06505647A (en) | 1994-06-30 |
US5409457A (en) | 1995-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5273530A (en) | Intraretinal delivery and withdrawal instruments | |
EP0764036B1 (en) | Method for preparation and transplantation of planar implants and surgical instruments therefor | |
Minckler | The organization of nerve fiber bundles in the primate optic nerve head | |
Nabih et al. | Experimental evaluation of perfluorophenanthrene as a high specific gravity vitreous substitute: a preliminary report | |
US6514238B1 (en) | Method for preparation and transplantation of volute grafts and surgical instrument therefor | |
US20060235068A1 (en) | Ophthalmological surgery colorant and delivery system | |
Wongpichedchai et al. | Comparison of external and internal approaches for transplantation of autologous retinal pigment epithelium. | |
Boone et al. | THE USE OF INTRAVTTREAL TISSUE PLASMINOGEN ACTIVATOR IN THE TREATMENT OF EXPERIMENTAL SUBRETINAL HEMORRHAGE IN THE PIG MODEL | |
Uram | Laser endoscope in the management of proliferative vitreoretinopathy | |
Allf et al. | In vivo cannulation of retinal vessels | |
Machemer et al. | The three-port microcannular system for closed vitrectomy | |
Charles et al. | Ganciclovir intraocular implant: a clinicopathologic study | |
Lazar et al. | A new procedure for multiple intraretinal transplantation into mammalian eyes | |
EP1447064B1 (en) | Kit-of-parts for surgically ablating eye tissue | |
Pederson et al. | Experimental retinal detachment: II. Role of the vitreous | |
Koch et al. | Subretinal microsurgery with gradient index endoscopes | |
Lambrou et al. | A new technique for subchoroidal implantation of experimental malignant melanoma. | |
Trese et al. | Experimental tractional retinal detachment in rabbits: clinical picture and histopathologic features | |
Schachat et al. | Tissue culture of human choroidal melanoma cells obtained by fine-needle aspiration biopsy | |
Occelli et al. | Subretinal transplantation of human embryonic stem cell-derived retinal tissue in a feline large animal model | |
Verdugo et al. | Posterior segment approach for subretinal transplantation or injection in the canine model | |
Miller et al. | Experimental vitrectomy: A lens-sparing technique in the rabbit eye | |
Mackool | Closed vitrectomy and the intraocular implant | |
Weichel et al. | Use of an oil-hydraulic microinjection pump for subretinal infusions | |
Shafer | Human vitreous transplantation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |